#United States #Naples #MC Sciences #Mikael Dolsten #ROC Venture Group

MC Sciences Appoints Dr. Mikael Dolsten as Independent Chairman

In a significant move, MC Sciences, a biotech firm focused on innovative therapies, has welcomed Dr. Mikael Dolsten as its new Independent Chairman. Dr. Dolsten, known for his prior role as Worldwide Chief Scientific Officer at Pfizer and President of Pfizer Research and Development, joins MC Sciences as it seeks to advance its mission of developing transformative therapeutics targeting mast cells, which are implicated in various serious conditions.

A Leader in Drug Development

Dr. Dolsten's expertise spans over 16 years at Pfizer, during which he oversaw the progression of more than 150 drug candidates into clinical trials and the approval of 36 medicines and vaccines. His extensive experience includes leadership positions at prominent organizations, such as Boehringer Ingelheim, Wyeth Research, and AstraZeneca. His accomplishments in drug discovery have positioned him as a respected figure in the pharmaceutical industry, enhancing MC Sciences' credibility.

Strengthening the Leadership Team

Wolfgang Taumann, CEO of MC Sciences, expressed excitement about Dr. Dolsten's appointment. He stated, "We are thrilled to be strengthening our leadership team with the addition of Mikael Dolsten to our Board. His unparalleled experience in advancing transformative medicines to patients will be instrumental in accelerating our promising first-in-class and transformative mast cell-targeting therapeutics to clinical development."

Vision for Transformation

Dr. Dolsten conveyed his enthusiasm for joining MC Sciences, noting, "I have been deeply impressed by the compelling science behind MC Sciences. Based on human pharmacology, the team has identified a novel mast cell receptor that controls the entire mast cell activity." He believes that the exceptional leadership of CEO Wolfgang Taumann and the scientific insights from Professor Gerhard J. Molderings create a significant opportunity to address diseases related to dysfunctional mast cells.

Addressing Unmet Medical Needs

Mast cells play a crucial role in several chronic conditions, ranging from dermatological issues to respiratory diseases, and lead to increased inflammatory responses. Dr. Dolsten pointed out that these diseases represent a major area of unmet medical need, particularly in fields such as dermatology, respiratory health, and inflammation-related disorders. The focus on developing therapeutics targeting mast cells is poised to revolutionize treatment options for conditions like chronic urticaria, systemic mastocytosis, and asthma, among others.

Milestone in Development

The addition of Dr. Dolsten to the team marks a pivotal step in MC Sciences' growth trajectory, bolstering its capabilities in drug development and deepening its scientific leadership. Aaron Stafford from ROC Venture Group, a key investor in MC Sciences, added, "As early investors, we believed in Wolfgang's vision and leadership and the transformative potential of MC Sciences from day one. With Dr. Dolsten joining, we enhance our team with executives who have a proven track record in delivering new drugs to patients."

Future Prospects

MC Sciences aims to propel its groundbreaking therapeutics into clinic trials, focusing on providing superior treatment options for mast cell-driven conditions. The company has already achieved compelling proof-of-concept data, setting the stage for significant future capital expansion during its upcoming Series-A funding round slated for Q4. Taumann reiterated the company’s commitment to delivering innovative therapies for diseases that remain inadequately addressed. The collaboration with Dr. Dolsten is anticipated to further energize their pursuit of effective solutions for patients battling chronic inflammatory conditions linked to mast cell dysfunction, expanding the frontiers of what is possible in therapeutic innovations.

About MC Sciences

MC Sciences is a pioneering biotechnology company dedicated to developing first-in-class therapeutics targeting mast cells across various disease indications. Founded with a commitment to innovation, the organization is headquartered in Germany, with operations extending to Naples, Florida, backed by leading investment groups like ROC Venture Group.

Dr. Dolsten’s appointment signifies not just an enhancement of leadership but embodies a concerted effort toward revolutionizing treatment pathways for millions who suffer from mast cell-related disorders. As the company continues on its journey, it aims to forge new paths in therapeutic development that prioritize patient care and scientific excellence.